483 related articles for article (PubMed ID: 25804315)
1. Reactive oxygen species and oxidative stress in osteoclastogenesis, skeletal aging and bone diseases.
Callaway DA; Jiang JX
J Bone Miner Metab; 2015 Jul; 33(4):359-70. PubMed ID: 25804315
[TBL] [Abstract][Full Text] [Related]
2. Reactive Oxygen Species in Osteoclast Differentiation and Possible Pharmaceutical Targets of ROS-Mediated Osteoclast Diseases.
Agidigbi TS; Kim C
Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31336616
[TBL] [Abstract][Full Text] [Related]
3. Ferric ion could facilitate osteoclast differentiation and bone resorption through the production of reactive oxygen species.
Jia P; Xu YJ; Zhang ZL; Li K; Li B; Zhang W; Yang H
J Orthop Res; 2012 Nov; 30(11):1843-52. PubMed ID: 22570238
[TBL] [Abstract][Full Text] [Related]
4. Melatonin, bone regulation and the ubiquitin-proteasome connection: A review.
Vriend J; Reiter RJ
Life Sci; 2016 Jan; 145():152-60. PubMed ID: 26706287
[TBL] [Abstract][Full Text] [Related]
5. Antioxidants, like coenzyme Q10, selenite, and curcumin, inhibited osteoclast differentiation by suppressing reactive oxygen species generation.
Moon HJ; Ko WK; Han SW; Kim DS; Hwang YS; Park HK; Kwon IK
Biochem Biophys Res Commun; 2012 Feb; 418(2):247-53. PubMed ID: 22252298
[TBL] [Abstract][Full Text] [Related]
6. Ormeloxifene inhibits osteoclast differentiation in parallel to downregulating RANKL-induced ROS generation and suppressing the activation of ERK and JNK in murine RAW264.7 cells.
Kharkwal G; Chandra V; Fatima I; Dwivedi A
J Mol Endocrinol; 2012 Jun; 48(3):261-70. PubMed ID: 22493142
[TBL] [Abstract][Full Text] [Related]
7. Coenzyme q10 regulates osteoclast and osteoblast differentiation.
Moon HJ; Ko WK; Jung MS; Kim JH; Lee WJ; Park KS; Heo JK; Bang JB; Kwon IK
J Food Sci; 2013 May; 78(5):H785-891. PubMed ID: 23582186
[TBL] [Abstract][Full Text] [Related]
8. Scoparone attenuates RANKL-induced osteoclastic differentiation through controlling reactive oxygen species production and scavenging.
Lee SH; Jang HD
Exp Cell Res; 2015 Feb; 331(2):267-77. PubMed ID: 25576385
[TBL] [Abstract][Full Text] [Related]
9. Mangiferin attenuates osteoclastogenesis, bone resorption, and RANKL-induced activation of NF-κB and ERK.
Ang E; Liu Q; Qi M; Liu HG; Yang X; Chen H; Zheng MH; Xu J
J Cell Biochem; 2011 Jan; 112(1):89-97. PubMed ID: 20683903
[TBL] [Abstract][Full Text] [Related]
10. Antioxidant alpha-lipoic acid inhibits osteoclast differentiation by reducing nuclear factor-kappaB DNA binding and prevents in vivo bone resorption induced by receptor activator of nuclear factor-kappaB ligand and tumor necrosis factor-alpha.
Kim HJ; Chang EJ; Kim HM; Lee SB; Kim HD; Su Kim G; Kim HH
Free Radic Biol Med; 2006 May; 40(9):1483-93. PubMed ID: 16632109
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of osteoclast differentiation and bone resorption by sauchinone.
Han KY; Yang D; Chang EJ; Lee Y; Huang H; Sung SH; Lee ZH; Kim YC; Kim HH
Biochem Pharmacol; 2007 Sep; 74(6):911-23. PubMed ID: 17662251
[TBL] [Abstract][Full Text] [Related]
12. Alternative NF-κB Regulates RANKL-Induced Osteoclast Differentiation and Mitochondrial Biogenesis via Independent Mechanisms.
Zeng R; Faccio R; Novack DV
J Bone Miner Res; 2015 Dec; 30(12):2287-99. PubMed ID: 26094846
[TBL] [Abstract][Full Text] [Related]
13. Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo.
Jimi E; Aoki K; Saito H; D'Acquisto F; May MJ; Nakamura I; Sudo T; Kojima T; Okamoto F; Fukushima H; Okabe K; Ohya K; Ghosh S
Nat Med; 2004 Jun; 10(6):617-24. PubMed ID: 15156202
[TBL] [Abstract][Full Text] [Related]
14. β-Adrenergic signaling stimulates osteoclastogenesis via reactive oxygen species.
Kondo H; Takeuchi S; Togari A
Am J Physiol Endocrinol Metab; 2013 Mar; 304(5):E507-15. PubMed ID: 23169789
[TBL] [Abstract][Full Text] [Related]
15. Bajijiasu Abrogates Osteoclast Differentiation via the Suppression of RANKL Signaling Pathways through NF-κB and NFAT.
Hong G; Zhou L; Shi X; He W; Wang H; Wei Q; Chen P; Qi L; Tickner J; Lin L; Xu J
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28106828
[TBL] [Abstract][Full Text] [Related]
16. RANKL-RANK signaling in osteoclastogenesis and bone disease.
Wada T; Nakashima T; Hiroshi N; Penninger JM
Trends Mol Med; 2006 Jan; 12(1):17-25. PubMed ID: 16356770
[TBL] [Abstract][Full Text] [Related]
17. Receptor activator of nuclear factor-kappaB ligand-induced mouse osteoclast differentiation is associated with switching between NADPH oxidase homologues.
Sasaki H; Yamamoto H; Tominaga K; Masuda K; Kawai T; Teshima-Kondo S; Matsuno K; Yabe-Nishimura C; Rokutan K
Free Radic Biol Med; 2009 Jul; 47(2):189-99. PubMed ID: 19409483
[TBL] [Abstract][Full Text] [Related]
18. Thapsigargin modulates osteoclastogenesis through the regulation of RANKL-induced signaling pathways and reactive oxygen species production.
Yip KH; Zheng MH; Steer JH; Giardina TM; Han R; Lo SZ; Bakker AJ; Cassady AI; Joyce DA; Xu J
J Bone Miner Res; 2005 Aug; 20(8):1462-71. PubMed ID: 16007343
[TBL] [Abstract][Full Text] [Related]
19. Oxidized low density lipoprotein decreases Rankl-induced differentiation of osteoclasts by inhibition of Rankl signaling.
Mazière C; Louvet L; Gomila C; Kamel S; Massy Z; Mazière JC
J Cell Physiol; 2009 Dec; 221(3):572-8. PubMed ID: 19725047
[TBL] [Abstract][Full Text] [Related]
20. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
